Figure 3.

Effect of single-dose therapeutic treatment using BTA938 for an influenza A/California/04/2009 (H1N1)pdm09 virus infection. Survival and body weight were monitored following a single treatment with the indicated doses of BTA938, beginning 4 h post-virus challenge. A significant difference in survival, compared with placebo, was observed for the 1, 3 and 10 mg/kg treatment groups (a). A significant difference in mean body weight, compared with placebo, was only observed for the 10 mg/kg treatment group (b). **P < 0.01. ***P < 0.001.